Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Conditions:   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Interventions:   Drug: Cyclophosphamide;   Biological: IRX-2;   Biological: Nivolumab;   Procedure: Surgery
Sponsors:   Emory University;   Bristol-Myers Squibb;   IRX Therapeutics
Not yet recruiting

https://ift.tt/2Ko15BP